Geode Capital Management
ZYBT

Geode Capital Management’s Zhengye Biotechnology Holding ZYBT Stock Holding History

Geode Capital Management’s Portfolio ZYBT Stock Details ZYBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7K Hold
29,068
– – ﹤0.01% 4376
2026
Q1 		$27.2K Hold
29,068
– – ﹤0.01% 4424
2025
Q4 		$33.4K Hold
29,068
– – ﹤0.01% 4309
2025
Q3 		$76.2K Hold
29,068
– – ﹤0.01% 4196
2025
Q2 		$174K Buy
+29,068
New +$231K ﹤0.01% 3920

Other funds holding ZYBT

WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Geode Capital Management's ZYBT Position: Q2 2026 in Review

Geode Capital Management held its Zhengye Biotechnology Holding (ZYBT) position steady in Q2 2026 at 29,068 shares worth $19.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4376.

Geode Capital Management first reported a position in ZYBT in Q2 2025 and has held it in 5 quarters since. The position peaked at $174K in Q2 2025. 6 funds tracked by Wall St. Rank hold ZYBT as of Q2 2026.

  • Geode Capital Management held 29,068 shares of Zhengye Biotechnology Holding worth $19.7K as of Q2 2026.
  • Geode Capital Management left its Zhengye Biotechnology Holding share count unchanged in Q2 2026.
  • Zhengye Biotechnology Holding made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4376 holding.
  • Geode Capital Management first reported a position in Zhengye Biotechnology Holding in Q2 2025 and has held it in 5 quarters since.
  • Geode Capital Management's Zhengye Biotechnology Holding position peaked at $174K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.